TLDR:
- Cardurion Pharmaceuticals, a startup founded seven years ago, raised $260 million in a Series B round led by Ascenta Capital.
- Ascenta Capital was established by former Moderna executives Lorence Kim and Evan Rachlin to focus on patient-centric and operator-centric investments.
Cardurion Pharmaceuticals, a cardiovascular startup founded seven years ago, has secured $260 million in funding for a Series B round. The funding round was led by Ascenta Capital, a venture capital fund started by former Moderna executives Lorence Kim and Evan Rachlin. Ascenta Capital, founded last year, prioritizes patient-centric and operator-centric investments, a philosophy that stems from both founders’ backgrounds in the pharmaceutical industry. Before making investment decisions, the founders of Ascenta Capital take the entire team, including administrative staff, to meet with patients affected by the diseases the startup is working on. This approach emphasizes the importance of understanding patient needs and experiences in the drug development process. The founders’ commitment to patient-centric investments sets Ascenta Capital apart in the venture capital landscape, creating a unique model for supporting cardiovascular startups like Cardurion Pharmaceuticals.
